Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Subviral Agents01:29

Subviral Agents

556
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
556
Air-entraining Agents01:27

Air-entraining Agents

270
Air-entraining agents improve the durability and workability of concrete in climates with frequent freezing and thawing. These agents prevent cracks by introducing small air bubbles into the mix, creating spaces accommodating water expansion when temperatures drop. The air-entraining agents lower the surface tension of water, forming stable, small air bubbles. This method is more effective than having accidental large voids, as the intentional, smaller, and evenly distributed air voids improve...
270
Masking and Demasking Agents01:19

Masking and Demasking Agents

3.6K
EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
3.6K
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

1.3K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

655
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
655
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.6K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Dosing Frequency and Dose Influence Thromboxane Suppression Despite Uniform Inhibition of Arachidonic Acid-induced Platelet Aggregation.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Poly(sulfobetaine-<i>co</i>-oligoethylene Glycol Methyl Ether Methacrylate) Copolymers with Improved Anti-Fouling and Anti-Coagulant Properties.

Biomacromolecules·2026
Same author

A novel biosensor for measuring plasmin activity.

Research and practice in thrombosis and haemostasis·2026
Same author

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71.

Blood·2026
Same author

Long-Term Hydrophilic, Anti-Clotting, and Anti-Fibrotic Dynamic Covalent Silicone-Based Biomaterials.

Advanced healthcare materials·2026
Same author

Pharmacologic Factor XI/XIa Inhibitors: What the Laboratory Hematologist Needs to Know.

Clinics in laboratory medicine·2026

Related Experiment Video

Updated: Jan 30, 2026

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
11:27

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

10.5K

Antithrombotic Agents.

Noel C Chan1, Jeffrey I Weitz1

  • 1From the Thrombosis and Atherosclerosis Research Institute and Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Circulation Research
|February 1, 2019
PubMed
Summary
This summary is machine-generated.

New antithrombotic strategies aim to improve safety. Lowering direct oral anticoagulant doses, using aspirin for venous thromboembolism, combining therapies, and developing factor XI/XII inhibitors offer better benefit-risk profiles.

Keywords:
ISIS 416858anticoagulantsaspirinfactor XIfactor XIIhemorrhagethrombosis

More Related Videos

Application of a Coupling Agent to Improve the Dielectric Properties of Polymer-Based Nanocomposites
06:34

Application of a Coupling Agent to Improve the Dielectric Properties of Polymer-Based Nanocomposites

Published on: September 19, 2020

6.3K
Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.
12:17

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.

Published on: March 17, 2008

16.0K

Related Experiment Videos

Last Updated: Jan 30, 2026

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
11:27

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

10.5K
Application of a Coupling Agent to Improve the Dielectric Properties of Polymer-Based Nanocomposites
06:34

Application of a Coupling Agent to Improve the Dielectric Properties of Polymer-Based Nanocomposites

Published on: September 19, 2020

6.3K
Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.
12:17

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.

Published on: March 17, 2008

16.0K

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Thrombin generation and platelet activation are key in arterial and venous thrombosis.
  • Current antithrombotic treatments carry a significant bleeding risk.
  • There is a need for safer anticoagulants and improved antithrombotic therapies.

Purpose of the Study:

  • To review recent trials enhancing the benefit-risk profile of antithrombotic therapy.
  • To discuss how new findings are changing the management of arterial and venous thrombosis.

Main Methods:

  • Review of recent clinical trials and scientific literature.
  • Analysis of treatment paradigms for arterial and venous thrombosis.
  • Discussion of novel antithrombotic agents and strategies.

Main Results:

  • Lowering direct oral anticoagulant doses can reduce bleeding without compromising efficacy in certain indications.
  • Aspirin demonstrates efficacy in secondary prevention of atherothrombosis and prevention of venous thromboembolism.
  • Dual pathway inhibition (low-dose rivaroxaban plus aspirin) shows superiority over monotherapy for preventing atherothrombosis.
  • Development of factor XI or XII inhibitors shows promise for safer anticoagulation.

Conclusions:

  • Optimizing antithrombotic therapy involves dose adjustments and combination strategies.
  • Novel agents like factor XI/XII inhibitors represent a future direction for safer anticoagulation.
  • These advances are reshaping the management of thrombotic disorders, balancing efficacy with reduced bleeding risk.